OMERS ADMINISTRATION Corp Purchases New Stake in Moderna, Inc. $MRNA

Key Points

• OMERS Administration Corp. acquired 13,458 Moderna shares worth approximately $942,000 in the second quarter, while institutional investors and hedge funds collectively own 75.33% of the company.
• Analyst sentiment remains mixed: William Blair upgraded Moderna to “outperform,” while the broader analyst consensus is “Hold,” with an average price target of $74.31. Targets range from $60 to $150.
• Moderna remains unprofitable, reporting a quarterly loss of $1.97 per share despite revenue of $145 million. Updated COVID-19 vaccine approvals and progress on its personalized cancer vaccine support its growth outlook, but a planned $2 billion convertible-notes offering raises dilution and funding concerns.

OMERS ADMINISTRATION Corp acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,458 shares of the company's stock, valued at approximately $942,000.

Other large investors have also recently bought and sold shares of the company. AQR Capital Management LLC acquired a new position in shares of Moderna in the 1st quarter valued at approximately $415,000. NewEdge Advisors LLC increased its stake in Moderna by 732.7% in the first quarter. NewEdge Advisors LLC now owns 11,575 shares of the company's stock valued at $328,000 after acquiring an additional 10,185 shares during the last quarter. United Services Automobile Association acquired a new position in Moderna during the first quarter valued at approximately $230,000. Focus Partners Wealth lifted its stake in Moderna by 58.7% during the first quarter. Focus Partners Wealth now owns 23,547 shares of the company's stock worth $668,000 after purchasing an additional 8,706 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in Moderna by 5.2% during the second quarter. American Century Companies Inc. now owns 48,859 shares of the company's stock worth $1,348,000 after purchasing an additional 2,410 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on MRNA. William Blair upgraded Moderna from a "market perform" rating to an "outperform" rating in a research note on Wednesday, August 19th. Citigroup upped their price objective on Moderna from $41.00 to $60.00 and gave the stock a "neutral" rating in a research report on Monday, August 3rd. Brookline Capital Markets reaffirmed a "buy" rating on shares of Moderna in a research note on Wednesday, August 19th. Loop Capital set a $135.00 target price on Moderna in a research report on Wednesday, August 19th. Finally, UBS Group boosted their target price on Moderna from $50.00 to $150.00 and gave the stock a "neutral" rating in a research note on Thursday, August 20th. Four equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat.com, Moderna presently has an average rating of "Hold" and an average target price of $74.31.

Insider Activity at Moderna

In other news, President Stephen Hoge sold 53,336 shares of the firm's stock in a transaction on Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president owned 1,483,848 shares of the company's stock, valued at approximately $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the transaction, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.80% of the stock is owned by company insiders.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: The FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, which target the XFG subvariant. The approval supports Moderna’s ability to participate in the upcoming seasonal vaccination market, although Spikevax eligibility is focused on adults 65 and older and higher-risk people ages 6 months through 64. FDA approves updated COVID vaccines
• Positive Sentiment: Renewed attention on Moderna and Merck’s personalized cancer vaccine, intismeran, is supporting the company’s long-term oncology story. Reports indicate the therapy reduced melanoma recurrence by approximately 49% in a late-stage study, strengthening expectations that Moderna could diversify beyond its declining COVID-19 business. Personalized melanoma vaccine results
• Neutral Sentiment: Moderna announced plans to raise $2 billion through convertible senior notes due in 2032, with an option for purchasers to increase the deal to $2.3 billion. Proceeds may fund oncology investments and debt repayment, while a hedge overlay is intended to offset dilution up to a specified cap. Moderna convertible notes offering
• Negative Sentiment: Investors are reacting cautiously to the financing because convertible notes can create future share dilution and signal substantial funding needs. The offering comes while Moderna remains unprofitable, making the company’s elevated valuation more difficult to justify on current earnings and revenue. Moderna borrows $2 billion

Moderna Trading Down 4.6%

NASDAQ MRNA opened at $142.77 on Friday. The company has a market cap of $57.00 billion, a price-to-earnings ratio of -17.87 and a beta of 0.91. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $176.66. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The business's fifty day moving average is $75.62 and its 200 day moving average is $59.17.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. During the same period last year, the company earned ($2.13) earnings per share. The business's quarterly revenue was up 2.1% on a year-over-year basis. As a group, sell-side analysts expect that Moderna, Inc. will post -6.18 EPS for the current fiscal year.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source